{
    "info": {
        "nct_id": "NCT05678205",
        "official_title": "A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors",
        "inclusion_criteria": "* ECOG performance status 0 to 1.\n* Histologically confirmed HER2 expressed breast or gastric/GEJ cancer IHC ≥ 2+ within 6 months prior to study entry.\n* Confirmed diagnosis of an advanced/unresectable or metastatic HER2+ breast or gastric/GEJ cancer that is refractory to, or intolerable of standard treatment, or for which no standard treatment is available.\n* Must have received prior cancer therapy: Subjects with breast cancer must have received ≥ 2 prior systemic therapies; subjects with gastric/GEJ cancer must have received ≥ 1 prior systemic therapy(ies); subjects with IHC 3+ or IHC 2+/ISH+ cancers must have received previous treatment with a HER2-targeting therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
        "exclusion_criteria": "* Known past or current malignancy other than inclusion diagnosis.\n* Known clinically significant cardiac disease.\n* Active central nervous system (CNS) metastases, or involvement of the CNS, unless there is a history of at least 3 months of sustained remission.\n* Unresolved toxicities from prior anticancer therapy.\n* Ongoing uncontrolled systemic infections requiring antibiotic, anti-fungal, or anti-viral therapy.\n* History of sensitivity or intolerance to cyclophosphamide or fludarabine.\n* Pregnant or lactating females and subjects of both sexes who are not willing to practice birth control from the time of consent through 6 months after administration of the last AB-201 dose.\n* Severe disease progression or health deterioration within 2 weeks prior to lymphodepletion regimen.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* ECOG performance status 0 to 1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0 to 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed diagnosis of an advanced/unresectable or metastatic HER2+ breast or gastric/GEJ cancer that is refractory to, or intolerable of standard treatment, or for which no standard treatment is available.",
            "criterions": [
                {
                    "exact_snippets": "Confirmed diagnosis of an advanced/unresectable or metastatic HER2+ breast or gastric/GEJ cancer",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cancer type",
                            "expected_value": [
                                "breast",
                                "gastric/GEJ"
                            ]
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory to, or intolerable of standard treatment, or for which no standard treatment is available",
                    "criterion": "response to standard treatment",
                    "requirements": [
                        {
                            "requirement_type": "refractory",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "intolerant",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "availability of standard treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 99 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 99 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 99,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have received prior cancer therapy: Subjects with breast cancer must have received ≥ 2 prior systemic therapies; subjects with gastric/GEJ cancer must have received ≥ 1 prior systemic therapy(ies); subjects with IHC 3+ or IHC 2+/ISH+ cancers must have received previous treatment with a HER2-targeting therapy.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with breast cancer must have received ≥ 2 prior systemic therapies",
                    "criterion": "prior systemic therapies for breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "number of prior systemic therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with gastric/GEJ cancer must have received ≥ 1 prior systemic therapy(ies)",
                    "criterion": "prior systemic therapies for gastric/GEJ cancer",
                    "requirements": [
                        {
                            "requirement_type": "number of prior systemic therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with IHC 3+ or IHC 2+/ISH+ cancers must have received previous treatment with a HER2-targeting therapy",
                    "criterion": "previous treatment with a HER2-targeting therapy for IHC 3+ or IHC 2+/ISH+ cancers",
                    "requirements": [
                        {
                            "requirement_type": "previous HER2-targeted therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed HER2 expressed breast or gastric/GEJ cancer IHC ≥ 2+ within 6 months prior to study entry.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed HER2 expressed breast or gastric/GEJ cancer",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cancer type",
                            "expected_value": [
                                "breast",
                                "gastric",
                                "gastroesophageal junction (GEJ)"
                            ]
                        },
                        {
                            "requirement_type": "HER2 expression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "IHC ≥ 2+ within 6 months prior to study entry",
                    "criterion": "HER2 immunohistochemistry (IHC) score",
                    "requirements": [
                        {
                            "requirement_type": "IHC score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "+"
                            }
                        },
                        {
                            "requirement_type": "time since IHC assessment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Ongoing uncontrolled systemic infections requiring antibiotic, anti-fungal, or anti-viral therapy.",
            "criterions": [
                {
                    "exact_snippets": "Ongoing uncontrolled systemic infections",
                    "criterion": "systemic infections",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring antibiotic, anti-fungal, or anti-viral therapy",
                    "criterion": "systemic infections",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "antibiotic therapy",
                                "anti-fungal therapy",
                                "anti-viral therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresolved toxicities from prior anticancer therapy.",
            "criterions": [
                {
                    "exact_snippets": "Unresolved toxicities from prior anticancer therapy",
                    "criterion": "toxicities from prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active central nervous system (CNS) metastases, or involvement of the CNS, unless there is a history of at least 3 months of sustained remission.",
            "criterions": [
                {
                    "exact_snippets": "Active central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "involvement of the CNS",
                    "criterion": "central nervous system (CNS) involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless there is a history of at least 3 months of sustained remission",
                    "criterion": "sustained CNS remission",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe disease progression or health deterioration within 2 weeks prior to lymphodepletion regimen.",
            "criterions": [
                {
                    "exact_snippets": "Severe disease progression ... within 2 weeks prior to lymphodepletion regimen",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to lymphodepletion regimen"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "health deterioration within 2 weeks prior to lymphodepletion regimen",
                    "criterion": "health deterioration",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to lymphodepletion regimen"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of sensitivity or intolerance to cyclophosphamide or fludarabine.",
            "criterions": [
                {
                    "exact_snippets": "History of sensitivity or intolerance to cyclophosphamide",
                    "criterion": "sensitivity or intolerance to cyclophosphamide",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of sensitivity or intolerance to ... fludarabine",
                    "criterion": "sensitivity or intolerance to fludarabine",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known past or current malignancy other than inclusion diagnosis.",
            "criterions": [
                {
                    "exact_snippets": "Known past or current malignancy other than inclusion diagnosis.",
                    "criterion": "malignancy (other than inclusion diagnosis)",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known clinically significant cardiac disease.",
            "criterions": [
                {
                    "exact_snippets": "Known clinically significant cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating females and subjects of both sexes who are not willing to practice birth control from the time of consent through 6 months after administration of the last AB-201 dose.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant or lactating females",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnant or lactating females",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects of both sexes who are not willing to practice birth control from the time of consent through 6 months after administration of the last AB-201 dose",
                    "criterion": "willingness to practice birth control",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}